TPO and ovarian carcinoma: Further proofs of the crucial role of IL-6 in paraneoplastic thrombocytosis have also been provided by molecular/genetic and pharmacological experiments: Silencing of Il-6 and tpo genes fully abrogated thrombocytosis in murine ovarian cancer, and siltuximab (humanized anti-IL-6 antibody) significantly reduced tumor growth and platelet count, both in murine and human ovarian cancers [28].